What are the diagnostic criteria and management options for Sjogren syndrome?

Sjögren Syndrome Diagnosis and Management

Diagnostic Criteria

Sjögren syndrome is diagnosed using a weighted scoring system where a total score of ≥4 points confirms the diagnosis in patients with suggestive signs and symptoms. 1

Scoring System (Total ≥4 points required):

High-Value Criteria (3 points each):

• Anti-SSA/Ro antibody positivity 1, 2
• Focal lymphocytic sialadenitis with focus score ≥1 foci/4 mm² on minor salivary gland biopsy 1, 2

Standard Criteria (1 point each):

• Abnormal ocular staining score ≥5 (or van Bijsterveld score ≥4) using lissamine green or fluorescein 1, 2
• Schirmer test ≤5 mm/5 minutes without anesthesia 1, 2
• Unstimulated salivary flow rate ≤0.1 ml/minute 1, 2

Clinical Suspicion Triggers

Suspect Sjögren syndrome in non-elderly women with intrinsic tear-production deficiency, especially if rapid in onset and/or marked in severity. 1

• Female-to-male ratio is 20:1 1, 2
• Prevalence approximately 0.4% of general population 1, 2
• Annual incidence 3.9-5.3 per 100,000 1, 2

Diagnostic Workup Algorithm

Step 1: Establish aqueous-deficient dry eye (ADDE)

• Use patient questionnaires combined with objective ocular tests 3
• Differentiate ADDE from evaporative dry eye using Schirmer test and tear film break-up time 3

Step 2: Serological testing

• Anti-SSA/Ro and anti-SSB/La antibodies 3, 4
• Antinuclear antibody (ANA) and rheumatoid factor 3
• Consider newer biomarkers (salivary gland protein-1, parotid secretory protein, carbonic anhydrase VI) for early or seronegative disease 3

Step 3: Assess salivary gland function

• Measure unstimulated whole salivary flow rate before therapeutic interventions 1
• Rule out non-Sjögren causes (candidiasis, burning mouth syndrome) 1
• Consider salivary scintigraphy 1

Step 4: Histological confirmation if needed

• Minor salivary gland biopsy showing focal lymphocytic sialadenitis 1, 3, 4

---

Management Approach

Critical Initial Steps

All patients with Sjögren syndrome must be co-managed with a rheumatologist due to potentially life-threatening systemic complications including vasculitis, lymphoproliferative disorders, and a 5% risk of lymphoma. 1, 2, 5

• Patients with decreased C4 levels at diagnosis have higher lymphoma risk and require closer monitoring 1, 2, 5
• Monitor for other ocular manifestations: scleritis, sterile keratitis, uveitis 1

Ocular Dryness Management

First-line therapy: Artificial tears containing methylcellulose or hyaluronate at least twice daily, increasing frequency up to hourly as needed based on symptoms and objective signs. 1

Stepwise approach:

• Topical lubricants and ocular gels/ointments provide volume replacement and reduce friction 1
• Topical anti-inflammatory therapy (cyclosporine) for moderate to severe dry eye 1
• Tear-conserving strategies (punctal plugs) 1
• Assess tear film stability, tear osmolarity, lid margin disease, and ocular surface damage to stage severity 1

Oral Dryness Management

Treatment algorithm based on residual salivary gland function:

Mild glandular dysfunction (first-line):

• Non-pharmacological stimulation with sugar-free acidic candies, lozenges, xylitol, or sugar-free chewing gum 1
• Preparations should have neutral pH and contain fluoride 1

Moderate glandular dysfunction:

• Pharmacological stimulation with muscarinic agonists (pilocarpine or cevimeline) 1
• Pilocarpine is licensed worldwide; cevimeline has better tolerance profile 1
• Expect high frequency of adverse events (cholinergic side effects) 1
• More effective for oral dryness than ocular dryness 1

Severe dysfunction (no salivary output):

• Saliva substitutes as preferred approach 1
• Available as oral sprays, gels, and rinses 1

Systemic Manifestations

Mild systemic disease:

• Consider hydroxychloroquine for fatigue and arthralgias (though evidence for dry eye efficacy is weak) 1, 2
• NSAIDs for joint pain and inflammation 2

Severe, refractory systemic disease:

• Sequential use of glucocorticoids, immunosuppressive agents, and biologics 2
• B-cell targeted therapies may be considered 2
• Anti-TNF agents are NOT effective 1
• Evidence for rituximab efficacy is not strong 1

---

Critical Pitfalls to Avoid

Do not miss the diagnosis: All patients with clinically significant ADDE should undergo serological assessment given potentially serious consequences including lymphoma risk 3

Do not rely solely on hydroxychloroquine for ocular symptoms: Despite common prescription for systemic symptoms, literature does not support efficacy for dry eye treatment 1

Do not use anti-TNF agents: These have been proven ineffective in controlled trials 1

Do not delay rheumatology referral: Early systemic evaluation and treatment may decrease morbidity and can be lifesaving 1

Monitor for lymphoma development: Approximately 5% of patients develop lymphoid malignancy, particularly those with decreased C4 levels 1, 2, 5